Phosplatin Therapeutics Announces $37 Million Series A Financing

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that it has completed a $37 million Series A financing. The round was led by Adinvest AG and included participation from existing investors, including the conversion of previously issued convertible notes.

Robert Fallon, President and Chief Executive Officer of Phosplatin Therapeutics, commented, "This is a major milestone for Phosplatin that adds the capital and resources needed to advance the clinical development of PT-112 for cancer patients who lack treatment options.  We are particularly pleased with the investment support for our clinical and translational research plan."

PT-112 is the first pyrophosphate-platinum conjugate with a unique mechanism of action that induces immunogenic cell death, leading to the recruitment of tumor-infiltrating lymphocytes, and associates with bone (osteotropism), due to its pyrophosphate moiety. Two trials are underway with PT-112: a monotherapy Phase 2 clinical trial in metastatic castration-resistant prostate cancer (mCRPC) patients; and the Phase 2a dose confirmation portion of an ongoing Phase 1b/2a clinical trial in combination with PD-L1 immune checkpoint inhibition in non-small cell lung cancer (NSCLC) patients. 

Dr. Neil Sunderland, Adinvest AG Chairman and lead investor, stated, "Phosplatin is advancing PT-112 based on compelling scientific validation, with top-tier collaborations. We see a range of promising opportunities ahead and are excited by the Company's prospects."

Dr. Sunderland serves as a Director of Phosplatin Therapeutics. He has invested in life science companies for many years and was a founding Partner of Montreux Growth Partners in San Francisco, a biotech and medtech growth capital firm.

Phosplatin has raised $74 million in equity capital since inception, and receives milestone fees from its sub-licensee for Greater China.

About PT-112
PT-112 is the first small-molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 may represent the best-in-class inducer of this immunological form of cancer cell death. Further, PT-112 harbors a property known as osteotropism, or the propensity of the drug to reach its highest concentrations in certain areas of the bone, making it a candidate for treatment of patients with cancers that originate in, or metastasize to, the bone. The ?rst in-human study of PT-112 demonstrated an attractive safety pro?le and evidence of long-lasting responses among heavily pre-treated patients and won "Best Poster" within the Developmental Therapeutics category at the ESMO 2018 Annual Congress. The combination Phase 1b dose escalation study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO 2020 Virtual Congress. The Phase 1 study in patients with relapsed or refractory multiple myeloma presented at ASH is the third completed Phase 1 study of PT-112. Monotherapy Phase 2 development is ongoing in mCRPC, and the PD-L1 combination study is ongoing in a dose confirmation cohort of NSCLC patients.

About Phosplatin Therapeutics
Phosplatin Therapeutics Inc. is a privately held, clinical stage pharmaceutical company that holds exclusive global license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with chemotherapeutic regimens. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death and osteotropism. Clinical data generated to date across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability pro?le, and two Phase 2 studies of PT-112 are underway. The company's research and development work to date has spanned sixteen countries and been funded by private investors and family investment of?ces in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with P?zer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active cooperative research and development agreement (CRADA) with the NCI to explore the use of PT-112 in thymic epithelial tumors.

CONTACTS:

Phosplatin Therapeutics
Brooke Raphael
VP Commercial Strategy & Operations
Email: [email protected]

ICR Westwicke
Investors:
Stephanie Carrington
Tel: +1 646 277 1282 
Email: [email protected]

Media: 
Mark Corbae
Tel: +1 203 682 8288 
Email: [email protected]

SOURCE Phosplatin Therapeutics